key: cord-035142-axyjd96e
authors: Zein, Joe G.; Whelan, Georgina; Erzurum, Serpil C.
title: Safety of influenza vaccine during COVID-19
date: 2020-09-17
journal: nan
DOI: 10.1017/cts.2020.543
sha: 
doc_id: 35142
cord_uid: axyjd96e

nan

. However, based on our data, influenza vaccine is not associated with increased pandemic COVID-19 severity, providing reassurance that the vaccination strategy for global influenza should proceed as planned during the COVID-19 pandemic.

Quantifying social distancing arising from pandemic influenza

Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)

Addressing extreme propensity scores via the overlap weights

The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines

The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement

Association between seasonal influenza vaccination in 2008-2009 and pandemic influenza A (H1N1) 2009 infection among school students from Kobe

Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada

Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection

BMI stands for body mass index; USD for US dollar; COPD for chronic obstructive pulmonary disease; NSAIDS for nonsteroidal anti-inflammatory drugs; ACE for angiotensin-converting enzyme; ARB for angiotensin receptor blocker; and ICU for Intensive Care Unit

Two unadjuvanted split virion, inactivated, quadrivalent influenza vaccines were provided to patients in 2019. A high-dose vaccine was given to patients 65 years and older

Acknowledgments. Supported by a grant from the National Heart, Lung and Blood Institute (NIH-NHLBI): K08 HL133381, TPPG PO1HL103453, RO1 HL60917, and UL1 TR002548.Disclosures. The authors have no conflicts of interest to declare.